about
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaLesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinolThe effect of angiotensin II receptor blockers on hyperuricemiaSLC transporters as therapeutic targets: emerging opportunitiesEngagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritisCatalysis and Structure of Zebrafish Urate Oxidase Provide Insights into the Origin of Hyperuricemia in HominoidsThe Structure, Thermodynamics and Solubility of Organic Crystals from Simulation with a Polarizable Force Field.Airway uric acid is a sensor of inhaled protease allergens and initiates type 2 immune responses in respiratory mucosaSerum apoprotein A1 levels are inversely associated with disease activity in gout: From a southern Chinese Han population.Expression and function of CXCL16 in a novel model of gout.Urate lowering therapy with febuxostat in daily practice-a multicentre, open-label, prospective observational study.2011 recommendations for the diagnosis and management of gout and hyperuricemia.Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis.Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?Comparison of activity indexes for recognizing enzyme mutants of higher activity with uricase as modelLong-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout.The role of uric acid as an endogenous danger signal in immunity and inflammation.The melanocortin agonist AP214 exerts anti-inflammatory and proresolving propertiesSerum uric acid level, blood pressure, and vascular angiotensin II responsiveness in healthy men and womenInnate and adaptive immune responses to cell death.An expanding role for interleukin-1 blockade from gout to cancer.Rising burden of gout in the UK but continuing suboptimal management: a nationwide population studyThe Association between Serum Uric Acid Levels and the Prevalence of Vulnerable Atherosclerotic Carotid Plaque: A Cross-sectional Study.Minimally important differences of the gout impact scale in a randomized controlled trial.Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting.Uric Acid Produces an Inflammatory Response through Activation of NF-κB in the Hypothalamus: Implications for the Pathogenesis of Metabolic DisordersUricases as therapeutic agents to treat refractory gout: Current states and future directions.Rhazes' prescriptions in treatment of gout.Efficacy and safety of febuxostat in patients with hyperuricemia and gout.A novel enzymatic approach in the production of food with low purine content using Arxula adeninivorans endogenous and recombinant purine degradative enzymes.Association between Gout and Erectile Dysfunction: A Systematic Review and Meta-Analysis.Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-ReviewMonosodium Urate Crystal-Induced Chondrocyte Death via Autophagic Process.Comorbidities in patients with gout prior to and following diagnosis: case-control study.Contribution of uric acid to cancer risk, recurrence, and mortality.Chronic hyperuricemia, uric acid deposit and cardiovascular riskPlasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysisTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases.2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.
P2860
Q24606766-0E968A29-BCAE-483C-A282-2A2668C32820Q24612292-A91F13CD-7480-4EBA-B6C3-137B1ADCF731Q24658504-0AC7C207-81BA-4774-AC4E-A3B3A7CC08D9Q26777082-D74C9D39-B5FF-4F29-9D9E-B7093F4B97C0Q27014726-A7A43EBB-1CC6-4204-B49E-1424BD465A7CQ28384291-387C1FAA-7988-4438-A208-12E5A0FD6C25Q28589525-D7E676D7-B806-4CC8-9234-EE2619CAA6F6Q30416702-2B0212C2-959B-4A30-BBEC-E8FE2043B6A9Q33581103-F140E41D-EE66-416B-B64F-532BAEA5172BQ33627261-20E94FD6-940C-48AB-928A-0728147E6A97Q34063348-7B17A5F3-8FAF-4C85-B1C4-C3583810BF94Q34207190-4938CE6B-1411-414E-9BE6-515995EA0568Q34250995-96AD2C62-D596-4689-9AE9-AD202B0AC42DQ34322559-E194DB87-D7C0-41E3-AE17-84C1A8BE3FD3Q34538414-98E18932-9A72-47DA-9218-825719DC88ECQ34675491-8A10A5BC-7B44-45D8-9B02-1FF5EDC67322Q34696782-A59BFB65-9F39-4776-AD67-0FD44C800624Q34977644-2C299BB2-8D23-4F79-B102-63FBED90D840Q35069961-4587D9A2-36E9-4942-87FA-55B97830FC2DQ35094181-75C0EEA1-CB0C-41CB-B568-12AC7BF344A7Q35205885-78E6CA8A-7B4D-49BF-80E6-4C7DD149CDC9Q35219001-FE85F028-332B-4FF0-B7E7-5653CA4F3618Q35352449-6C9423DC-C253-4F15-903F-D2D4497BE680Q35591199-2714E842-6106-47B2-9F54-5AAF5DC1F353Q35839395-28606E28-BAF5-468B-88C7-C8AB0DC0B46EQ35849062-1AE5F416-171F-4B13-AEA8-875D32629161Q35856483-3BA04565-A8E3-4ABA-A98F-D393597801D8Q36002499-828700AE-5C3F-4108-826E-AF97B7EB9941Q36022665-9B8D3B24-D06E-4AF5-B18D-19984A531BD1Q36059557-55A3D04C-C9E5-4262-8882-B6B9A1A7D2C7Q36147138-31F9EA47-C740-43E0-AB71-832EFFFA80A2Q36236512-5FAC581A-5732-4CE2-8CA3-C00B6191F54FQ36255567-2C281354-316F-4536-BCF1-58F235A478D2Q36404177-3593C15B-DA6D-4E95-8393-BA2CE8A4D8AAQ36475590-BB638188-E25C-46BF-86CF-C91FA24F6A06Q36578207-B1FE606A-E7DF-4264-AB83-952C3214C3E1Q36712438-1BC68EAD-F7BA-4694-8FC9-830FF0377411Q36724236-69C91114-8317-4694-9EFF-5B690B5CCC9FQ36816872-761B6028-8056-4581-A92D-121E69A3EF1DQ36870924-80A8B8CD-35E2-4210-A500-802F83EC8EC4
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Update on gout: new therapeutic strategies and options.
@ast
Update on gout: new therapeutic strategies and options.
@en
Update on gout: new therapeutic strategies and options.
@nl
type
label
Update on gout: new therapeutic strategies and options.
@ast
Update on gout: new therapeutic strategies and options.
@en
Update on gout: new therapeutic strategies and options.
@nl
prefLabel
Update on gout: new therapeutic strategies and options.
@ast
Update on gout: new therapeutic strategies and options.
@en
Update on gout: new therapeutic strategies and options.
@nl
P356
P1476
Update on gout: new therapeutic strategies and options.
@en
P2093
Robert Terkeltaub
P2888
P356
10.1038/NRRHEUM.2009.236
P407
P577
2010-01-01T00:00:00Z
P6179
1016699723